Data Provide New Clinical Insights on Use of Veklury for Treatment of COVID-19 – – Research Examines Strategies to Enhance the Participation of Communities Underrepresented in HIV Clinical Trials – Gilead Sciences, Inc. today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 – …
Data Provide New Clinical Insights on Use of Veklury for Treatment of COVID-19 –
– Research Examines Strategies to Enhance the Participation of Communities Underrepresented in HIV Clinical Trials –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 – October 3. The findings in COVID-19 research, HIV treatment research and HIV prevention research are the latest example of Gilead’s ongoing commitment to help address the evolving COVID-19 pandemic and the needs of people affected by HIV.
“In partnership with the infectious disease community, we continue to monitor and respond to the devastating global viral pandemic, while simultaneously working to maintain the tremendous progress that has been made toward ending the HIV epidemic,” said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “Our antiviral research program is not only expanding the scientific understanding of our...
Read Full Story: https://investingnews.com/news/biotech-investing/gilead-to-present-latest-antiviral-research-data-addressing-urgent-global-needs-in-infectious-disease-at-idweek-2021/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.